The company reported total revenues at a record $84.7 million, compared with $41.4 million for the same period in 2020. Contract revenue was $13.6 million, compared with $9.8 million for the same period in 2020. Company leaders said the increase is mainly due to the timing of partner milestone events and the acquisition of Pfenex in October 2020.

Net income for the second quarter was $30.7 million versus a net income of $22.1 million for the same period in 2020.

Company leaders said they anticipate multiple regulatory approvals of drugs based on the company's technologies that will drive royalty revenue in 2022 and beyond.

iMetabolic, Ligand partner on OmniAb development
iMetabolic Biopharma has announced an expansion of its partnership with Ligand Pharmaceuticals that will give it access to Ligand's OmniAb antibody discovery...

Ligand expands antibody discovery capabilities with acquisitions
Ligand Pharmaceuticals has acquired xCella Biosciences and Taurus Biosciences to strengthen its OmniAb technology platform for antibody discovery.

Ligand expands oncology drug discovery with Servier
Ligand Pharmaceuticals subsidiary Vernalis Research has expanded its oncology drug discovery collaboration with French pharmaceutical company Servier.

Ligand, Roche to develop ion channel drug discovery platform
Ligand Pharmaceuticals and Icagen have expanded Icagen's license agreement with Roche to develop and commercialize small molecule ion channel modulators...